Erleada and Theraflu Nighttime Severe Cold
Determining the interaction of Erleada and Theraflu Nighttime Severe Cold and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Consumer information for this interaction is not currently available.MONITOR: Coadministration with apalutamide may decrease the plasma concentrations and therapeutic effects of drugs that are substrates of CYP450 3A4, 2C9, 2C19, breast cancer resistance protein (BCRP), uridine diphosphate glucuronosyltransferase (UGT), organic anion transporting polypeptide 1B1 (OATP1B1), and/or P-glycoprotein (P-gp) efflux transporter. The proposed mechanism involves accelerated clearance via these routes due to apalutamide-mediated induction. The resulting plasma concentrations will depend on the sensitivity of the affected drugs to these isoenzymes. MANAGEMENT: Caution is advised when apalutamide is used concomitantly with drugs that are substrates of CYP450 3A4, 2C9, 2C19, BCRP, UGT, OATP1B1, and/or P-gp, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever apalutamide is added to or withdrawn from therapy. References "Product Information. Erleada (apalutamide)." Janssen Biotech, Inc., Horsham, PA, PA. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
Professional:MONITOR: Coadministration with apalutamide may decrease the plasma concentrations and therapeutic effects of drugs that are substrates of CYP450 3A4, 2C9, 2C19, breast cancer resistance protein (BCRP), uridine diphosphate glucuronosyltransferase (UGT), organic anion transporting polypeptide 1B1 (OATP1B1), and/or P-glycoprotein (P-gp) efflux transporter. The proposed mechanism involves accelerated clearance via these routes due to apalutamide-mediated induction. The resulting plasma concentrations will depend on the sensitivity of the affected drugs to these isoenzymes.
MANAGEMENT: Caution is advised when apalutamide is used concomitantly with drugs that are substrates of CYP450 3A4, 2C9, 2C19, BCRP, UGT, OATP1B1, and/or P-gp, particularly those with a narrow therapeutic range. Dosage adjustments as well as clinical and laboratory monitoring may be appropriate for some drugs whenever apalutamide is added to or withdrawn from therapy.
- "Product Information. Erleada (apalutamide)." Janssen Biotech, Inc., Horsham, PA, PA.
- Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0
Generic Name: acetaminophen / pheniramine / phenylephrine
Brand name: Flu & Severe Cold Night Time, Theraflu Flu & Sore Throat, Theraflu Nighttime Severe Cold, Theraflu Sinus & Cold, Theraflu Cold & Sore Throat, Theraflu Cold and Sore Throat, Theraflu Flu and Sore Throat
Synonyms: Theraflu Flu & Sore Throat
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Erleada-Theraflu Nighttime Severe Cough and Cold
- Erleada-Theraflu PowerPods (Acetaminophen, Dextromethorphan, and Phenylephrine Pods)
- Erleada-Theraflu PowerPods (Acetaminophen, Diphenhydramine, and Phenylephrine Pods)
- Erleada-Theraflu Severe Cold & Congestion
- Erleada-Theraflu Severe Cold & Congestion Non-Drowsy
- Erleada-Theraflu Severe Cold & Cough Nighttime
- Theraflu Nighttime Severe Cold-Erlotinib
- Theraflu Nighttime Severe Cold-Erlotinib Tablets
- Theraflu Nighttime Severe Cold-Errin
- Theraflu Nighttime Severe Cold-Ertapenem
- Theraflu Nighttime Severe Cold-Ertapenem Injection
- Theraflu Nighttime Severe Cold-Ertapenem Sodium